- Home
- PBYI vs SAVA Comparison
PBYI vs SAVA Comparison
Compare PBYI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SAVA
- Stock Information
- Founded
- PBYI 2010
- SAVA 1998
- Country
- PBYI United States
- SAVA United States
- Employees
- PBYI N/A
- SAVA N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- SAVA Health Care
- Exchange
- PBYI Nasdaq
- SAVA Nasdaq
- Market Cap
- PBYI 153.2M
- SAVA 134.2M
- IPO Year
- PBYI N/A
- SAVA N/A
- Fundamental
- Price
- PBYI $2.92
- SAVA $2.55
- Analyst Decision
- PBYI Strong Buy
- SAVA Buy
- Analyst Count
- PBYI 1
- SAVA 3
- Target Price
- PBYI $7.00
- SAVA $111.50
- AVG Volume (30 Days)
- PBYI 416.5K
- SAVA 12.4M
- Earning Date
- PBYI 11-07-2024
- SAVA 11-07-2024
- Dividend Yield
- PBYI N/A
- SAVA N/A
- EPS Growth
- PBYI 492.79
- SAVA N/A
- EPS
- PBYI 0.47
- SAVA N/A
- Revenue
- PBYI $243,569,000.00
- SAVA N/A
- Revenue This Year
- PBYI N/A
- SAVA N/A
- Revenue Next Year
- PBYI N/A
- SAVA N/A
- P/E Ratio
- PBYI $6.26
- SAVA N/A
- Revenue Growth
- PBYI 6.30
- SAVA N/A
- 52 Week Low
- PBYI $2.23
- SAVA $2.55
- 52 Week High
- PBYI $7.73
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- PBYI 47.45
- SAVA 22.85
- Support Level
- PBYI $2.82
- SAVA $2.78
- Resistance Level
- PBYI $3.12
- SAVA $3.28
- Average True Range (ATR)
- PBYI 0.20
- SAVA 0.26
- MACD
- PBYI -0.03
- SAVA 0.25
- Stochastic Oscillator
- PBYI 14.71
- SAVA 0.00
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.